• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Beam Therapeutics Inc.

    2/27/24 7:40:17 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email
    S-8 1 2024_s-8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    BEAM THERAPEUTICS INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    81-5238376

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

     

    238 Main St., Cambridge, MA

    02142

    (Address of Principal Executive Offices)

    (Zip Code)

    Beam Therapeutics Inc. 2019 Equity Incentive Plan

    Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan

    (Full title of the plan)

    John Evans

    Chief Executive Officer

    Beam Therapeutics Inc.

    238 Main Street

    Cambridge, MA 02142

    (Name and address of agent for service)

    (857) 327-8775

    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement has been filed by the Beam Therapeutics Inc. (the “Registrant”) to register (i) 3,265,299 additional shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), available for issuance under the Beam Therapeutics Inc. 2019 Equity Incentive Plan and (ii) 816,324 additional shares of Common Stock available for issuance under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan. This Registration Statement relates to securities of the same class as those that were previously registered by the Registrant on Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2020 (File No. 333-236582), March 17, 2021 (File No. 333-254378), February 28, 2022 (File No. 333-263067), and February 28, 2023 (File No. 333-270079).

    Pursuant to General Instruction E to Form S-8 regarding registration of additional securities, the entire contents of the Registration Statements reference above are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents which have been previously filed (not furnished) with the SEC:

    (a)

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 27, 2024 (File No. 001-39208);

     

     

     

     

    (b)

    the information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K for the year ended December 31, 2022 from the Registrant's Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 21, 2023;

    (c)

    the Registrant’s Current Report on Form 8-K, as filed with the SEC on January 8, 2024 (with respect to Item 8.01); and

    (d)

    the description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the SEC on January 31, 2020 pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as the description therein has been updated and superseded by the description of the Registrant’s Common Stock contained in Exhibit 4.11 to the Registrant’s Registration Statement on Form S-3 (File No. 333-254946) filed with the SEC on April 1, 2021, and including any amendments or reports filed for the purpose of updating such description.

    In addition, all other documents filed (not furnished) by the Registrant pursuant to Section 13(a), Section 13(c), Section 14 or Section 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated in this Registration Statement by reference and to be a part of this Registration Statement from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished to and not filed with the SEC in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


     

    Item 8.

    Exhibits.

    The following exhibits are filed with or incorporated by reference into this Registration Statement:

     

     

     

    Exhibit

    No.

    Description

     

     

    4.1

    Fourth Amended and Restated Certificate of Incorporation of the Registrant (previously filed as Exhibit 3.1 to the current report Form 8-K filed on February 11, 2020 (File No. 001-39208) and incorporated herein by reference).

     

     

    4.2

    Amended and Restated Bylaws of the Registrant (previously filed as Exhibit 3.2 to the Annual Report on Form 10-K filed on February 28, 2023 (File No. 001-39208) and incorporated herein by reference).

     

     

    5.1

    Opinion of Wilmer Cutler Pickering Hale & Dorr LLP (filed herewith).

     

     

    23.1

    Consent of Deloitte & Touche LLP (filed herewith).

     

     

    23.2

    Consent of Wilmer Cutler Pickering Hale & Dorr LLP (included within the opinion filed as Exhibit 5.1).

     

     

    24.1

    Power of Attorney (included on signature page to this Registration Statement).

     

     

    99.1

    Beam Therapeutics Inc. 2019 Equity Incentive Plan (previously filed as Exhibit 10.16 to the registration statement on Form S-1 (File No. 333-233985) and incorporated herein by reference).

     

     

    99.2

    Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan (previously filed as Exhibit 10.27 to the annual report on Form 10-K filed on February 28, 2022 (File No. 001-39208) and incorporated herein by reference).

     

     

    107.1

    Filing Fee Table

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 27th day of February, 2024.

    BEAM THERAPEUTICS INC.

     

     

    By:

    /s/ John Evans

     

    John Evans

     

    Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints John Evans, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Beam Therapeutics Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

    Name and Signature

    Title

    Date

     

     

     

    /s/ John Evans

    Chief Executive Officer and Director

     

    John Evans

    (Principal Executive Officer)

    February 27, 2024

     

     

     

    /s/ Terry-Ann Burrell

    Chief Financial Officer

     

    Terry-Ann Burrell

    (Principal Financial Officer and Principal Accounting Officer)

    February 27, 2024

     

     

     

    /s/ Kristina Burow

    Director

    February 27, 2024

    Kristina Burow

     

     

     

     

     

    /s/ Graham Cooper

    Director

    February 27, 2024

    Graham Cooper

     

     

     

     

     

    /s/ Mark Fishman

    Director

    February 27, 2024

    Mark Fishman, M.D.

     

     

     

     

     

    /s/ Carole Ho

    Director

    February 27, 2024

    Carole Ho, M.D.

     

     

     

     

     

    /s/ John Maraganore

    Director

    February 27, 2024

    John Maraganore, Ph.D.

     

     

     

     

     

     

     

    /s/ Christi Shaw

    Director

    February 27, 2024

    Christi Shaw

     

     

     

     

     

    /s/ Kathleen Walsh

    Director

    February 27, 2024

    Kathleen Walsh

     

     

     


    Get the next $BEAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    10/9/2025$41.00Buy
    Jefferies
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Bellon Christine

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    2/2/26 4:05:09 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President Ciaramella Giuseppe

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    2/2/26 4:05:16 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Emany Sravan Kumar

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    2/2/26 4:05:13 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Beam Therapeutics Inc.

    SCHEDULE 13G - Beam Therapeutics Inc. (0001745999) (Subject)

    2/9/26 6:19:08 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Beam Therapeutics Inc. (0001745999) (Filer)

    2/5/26 4:05:25 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

    SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    2/5/26 2:56:50 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Beam Therapeutics with a new price target

    Jefferies initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $41.00

    10/9/25 12:13:51 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

    3/28/25 8:10:19 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics upgraded by Scotiabank with a new price target

    Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

    3/10/25 11:54:09 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

    Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026   Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bea

    1/11/26 5:00:00 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision g

    12/18/25 4:01:00 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

    Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom management[2]. Five companies positioned at this convergence include Avant Technologies, Inc. (OTCQB:AVAI), Beam Therapeutics Inc. (NASDAQ:BEAM), CRISPR Therapeutics (NASDAQ:CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ:R

    12/9/25 11:57:00 AM ET
    $BEAM
    $CRSP
    $RCKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BEAM
    Leadership Updates

    Live Leadership Updates

    View All

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

    CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

    12/4/24 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

    CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

    12/14/23 6:30:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/12/24 9:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/7/24 9:56:02 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    10/17/24 11:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    Financials

    Live finance-specific insights

    View All

    Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

    Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

    6/13/25 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

    Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

    5/14/25 9:30:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

    Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

    3/10/25 6:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care